METHOD FOR MINIMALLY INVASIVE DIAGNOSIS OF MENINGIOMAS AND GLIAL TUMORS WITH SPECIFICATION OF THE DEGREE OF MALIGNANCY Russian patent published in 2023 - IPC G01N33/574 C12Q1/6806 C12Q1/686 C12Q1/6876 C12Q1/6886 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to molecular oncology, and can be used for minimally invasive diagnosis of meningiomas and glial tumors with specification of the degree of malignancy. Microrna expression is analyzed in the plasma sample. High specific primers are used for hsa-miR-21-5p, hsa-miR-342-3p, hsa-miR-3180-3, hsa-let-7c-5p, hsa-miR-190b-5p and cel-miR-39 -5p. The values are calculated cel-miR-39-5p, ΔCt hsa-miR-3180-3p = Ct hsa-miR-3180-3p – Ct cel-miR-39-5p, ΔCt hsa-let-7c-5p = Ct hsa-let -7c-5p – Ct cel-miR-39-5p, ΔCt hsa-miR-190b-5p = Ct hsa-miR-190b-5p – Ct cel-miR-39-5p, where Ct is the threshold cycle number after which an increase in signal relative to background values is achieved. With a value of ΔCt hsa-miR-21-5p ≥ 1.7, meningioma is diagnosed. With the values ΔCt hsa-miR-21-5p < 1.7, ΔCt hsa-miR-342-3p ≥ 2.9 and ΔCt hsa-miR-3180-3p < 13, glioma is diagnosed. With a value of ΔCt hsa-miR-21-5p < -1.4, the GIV degree of malignancy is determined - glioblastoma. At the values of ΔCt hsa-let-7c-5p < 0.76 and ΔCt hsa-miR-190b-5p < 10, grade GIII of malignancy is established - anaplastic astrocytoma. At values of ΔCt hsa-let-7c-5p < 0.76 and ΔCt hsa-miR-190b-5p < 10, GII degree of malignancy is established - diffuse astrocytoma.

EFFECT: method provides for the creation and implementation of a new, universal, inexpensive and accurate test system for the diagnosis of the most common primary brain tumors, in particular meningiomas and glial tumors, through the use of highly specific primers for hsa-miR-21-5p, hsa-miR- 342-3p, hsa-miR-3180-3, hsa-let-7c-5p, hsa-miR-190b-5p and cel-miR-39-5p.

1 cl, 1 tbl, 4 ex